Enrofloxacin: pharmacokinetics and metabolism in domestic animal species. 2013

Cristina López-Cadenas, and Matilde Sierra-Vega, and Juan J García-Vieitez, and M José Diez-Liébana, and Ana Sahagún-Prieto, and Nélida Fernández-Martínez

Enrofloxacin is a fluorquinolone exclusively developed for use in veterinary medicine (1980). The kinetics of enrofloxacin are characterized, in general terms, by high bioavailability in most species and rapid absorption after IM, SC or oral administration. However, several studies reported that enrofloxacin showed low bioavailability after oral administration in ruminants. This drug has a broad distribution in the organism, excellent tissue penetration and long serum half-life. Also, enrofloxacin is characterized by a low host toxicity, a broad antibacterial spectrum and high bactericidal activity against major pathogenic bacteria (both Gram-positive and Gram-negative), and intracellular organisms found in diseased animals. The kinetics vary according to the route of administration, formulation, animal species, age, body condition, and physiological status, all of which contribute to differences in drug efficacy. The pharmacokinetic properties of drugs are closely related to their pharmacological efficiency, so it is important to know their behavior in each species that is used. This article reviews the pharmacokinetics of enrofloxacin in several domestic animal species.

UI MeSH Term Description Entries
D007408 Intestinal Absorption Uptake of substances through the lining of the INTESTINES. Absorption, Intestinal
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077422 Enrofloxacin A fluoroquinolone antibacterial and antimycoplasma agent that is used in veterinary practice. Bay Vp 2674,Bay-Vp-2674,Baytril,Endrofloxicin
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000829 Animals, Domestic Animals which have become adapted through breeding in captivity to a life intimately associated with humans. They include animals domesticated by humans to live and breed in a tame condition on farms or ranches for economic reasons, including LIVESTOCK (specifically CATTLE; SHEEP; HORSES; etc.), POULTRY; and those raised or kept for pleasure and companionship, e.g., PETS; or specifically DOGS; CATS; etc. Farm Animals,Domestic Animals,Domesticated Animals,Animal, Domestic,Animal, Domesticated,Animal, Farm,Animals, Domesticated,Animals, Farm,Domestic Animal,Domesticated Animal,Farm Animal
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D001424 Bacterial Infections Infections by bacteria, general or unspecified. Bacterial Disease,Bacterial Infection,Infection, Bacterial,Infections, Bacterial,Bacterial Diseases
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities

Related Publications

Cristina López-Cadenas, and Matilde Sierra-Vega, and Juan J García-Vieitez, and M José Diez-Liébana, and Ana Sahagún-Prieto, and Nélida Fernández-Martínez
January 2009, Veterinary journal (London, England : 1997),
Cristina López-Cadenas, and Matilde Sierra-Vega, and Juan J García-Vieitez, and M José Diez-Liébana, and Ana Sahagún-Prieto, and Nélida Fernández-Martínez
September 1976, Archives internationales de pharmacodynamie et de therapie,
Cristina López-Cadenas, and Matilde Sierra-Vega, and Juan J García-Vieitez, and M José Diez-Liébana, and Ana Sahagún-Prieto, and Nélida Fernández-Martínez
January 1979, British journal of clinical pharmacology,
Cristina López-Cadenas, and Matilde Sierra-Vega, and Juan J García-Vieitez, and M José Diez-Liébana, and Ana Sahagún-Prieto, and Nélida Fernández-Martínez
June 2004, Journal of veterinary pharmacology and therapeutics,
Cristina López-Cadenas, and Matilde Sierra-Vega, and Juan J García-Vieitez, and M José Diez-Liébana, and Ana Sahagún-Prieto, and Nélida Fernández-Martínez
October 2014, Research in veterinary science,
Cristina López-Cadenas, and Matilde Sierra-Vega, and Juan J García-Vieitez, and M José Diez-Liébana, and Ana Sahagún-Prieto, and Nélida Fernández-Martínez
January 1986, Journal of cardiovascular pharmacology,
Cristina López-Cadenas, and Matilde Sierra-Vega, and Juan J García-Vieitez, and M José Diez-Liébana, and Ana Sahagún-Prieto, and Nélida Fernández-Martínez
June 2003, Annals of the New York Academy of Sciences,
Cristina López-Cadenas, and Matilde Sierra-Vega, and Juan J García-Vieitez, and M José Diez-Liébana, and Ana Sahagún-Prieto, and Nélida Fernández-Martínez
April 2004, Journal of veterinary pharmacology and therapeutics,
Cristina López-Cadenas, and Matilde Sierra-Vega, and Juan J García-Vieitez, and M José Diez-Liébana, and Ana Sahagún-Prieto, and Nélida Fernández-Martínez
January 2010, Handbook of experimental pharmacology,
Cristina López-Cadenas, and Matilde Sierra-Vega, and Juan J García-Vieitez, and M José Diez-Liébana, and Ana Sahagún-Prieto, and Nélida Fernández-Martínez
December 1997, British poultry science,
Copied contents to your clipboard!